Jayne, David R W <br/><br/>
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.  [electronic resource] 

 -  Journal of the American Society of Nephrology : JASN  Sep 2017 
 - 2756-2767 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1533-3450 
<br/><br/><label>Standard No.: </label>10.1681/ASN.2016111179  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aniline Compounds--adverse effects<br/>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis--drug therapy<br/>Cyclophosphamide--therapeutic use<br/>Double-Blind Method<br/>Drug Therapy, Combination--adverse effects<br/>Female<br/>Glucocorticoids--administration & dosage<br/>Humans<br/>Immunosuppressive Agents--therapeutic use<br/>Male<br/>Middle Aged<br/>Nipecotic Acids--adverse effects<br/>Prednisone--administration & dosage<br/>Receptor, Anaphylatoxin C5a--antagonists & inhibitors<br/>Rituximab--therapeutic use<br/>Severity of Illness Index